Rett syndrome and the urge of novel approaches to study MeCP2 functions and mechanisms of action

Neuroscience and Biobehavioral Reviews

Volumn 46, Issue P2, 2014, Pages 187-201

  Bedogni, Francesco ^a,b   Rossi, Riccardo L ^c   Galli, Francesco ^a   Cobolli Gigli, Clementina ^a,b   Gandaglia, Anna ^a,b   Kilstrup Nielsen, Charlotte ^b   Landsberger, Nicoletta ^a,b  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b UNIVERSITY OF INSUBRIA   (Italy)

^c Istituto Nazionale di Genetica Molecolare   (Italy)

Author keywords

MeCP2; Molecular genetics; Pathway enrichment analysis; Perturbation in gene expression; Rett syndrome; Structure and function

Indexed keywords

METHYL CPG BINDING PROTEIN 2;

CELL METABOLISM; CYTOSKELETON; GENE FUNCTION; GENE MUTATION; GENE STRUCTURE; GENETIC TRANSCRIPTION; HUMAN; INTELLECTUAL IMPAIRMENT; MECP2 GENE; MOLECULAR GENETICS; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PHENOTYPE; RETT SYNDROME; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; BIOLOGY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM;

ANIMALS; COMPUTATIONAL BIOLOGY; GENE EXPRESSION REGULATION, DEVELOPMENTAL; HUMANS; METHYL-CPG-BINDING PROTEIN 2; RETT SYNDROME; SIGNAL TRANSDUCTION;

EID: 84909644903     PISSN: 01497634     EISSN: 18737528     Source Type: Journal    
DOI: 10.1016/j.neubiorev.2014.01.011     Document Type: Review

References (115)

1. Abuhatzira L., Shemer R., Razin A. MeCP2 involvement in the regulation of neuronal alpha-tubulin production. Hum. Mol. Genet. 2009, 18:1415-1423.
2. Adams V.H., McBryant S.J., Wade P.A., Woodcock C.L., Hansen J.C. Intrinsic disorder and autonomous domain function in the multifunctional nuclear protein, MeCP2. J. Biol. Chem. 2007, 282:15057-15064.
3. Agarwal N., Hardt T., Brero A., Nowak D., Rothbauer U., Becker A., Leonhardt H., Cardoso M.C. MeCP2 interacts with HP1 and modulates its heterochromatin association during myogenic differentiation. Nucleic Acids Res. 2007, 35:5402-5408.
4. Archer H.L., Evans J.C., Millar D.S., Thompson P.W., Kerr A.M., Leonard H., Christodoulou J., Ravine D., Lazarou L., Grove L., Verity C., Whatley S.D., Pilz D.T., Sampson J.R., Clarke A.J. NTNG1 mutations are a rare cause of Rett syndrome. Am. J. Med. Genet. A 2006, 140:691-694.
5. Armstrong D.D. The neuropathology of the Rett syndrome. Brain Dev. 1992, 14:S89-S98.
6. Baker S.A., Chen L., Wilkins A.D., Yu P., Lichtarge O., Zoghbi H.Y. An AT-hook domain in MeCP2 determines the clinical course of Rett syndrome and related disorders. Cell 2013, 152:984-986.
7. Ballas N., Lioy D.T., Grunseich C., Mandel G. Non-cell autonomous influence of MeCP2-deficient glia on neuronal dendritic morphology. Nat. Neurosci. 2009, 12:311-317.
8. Bebbington A., Anderson A., Ravine D., Fyfe S., Pineda M., de Klerk N., Ben-Zeev B., Yatawara N., Percy A., Kaufmann W.E., Leonard H. Investigating genotype-phenotype relationships in Rett syndrome using an international data set. Neurology 2008, 70:868-875.
9. Belichenko P.V., Hagberg B., Dahlström A. Morphological study of neocortical areas in Rett syndrome. Acta Neuropathol. 1997, 93:50-61.
10. Belichenko P.V., Wright E.E., Belichenko N.P., Masliah E., Li H.H., Mobley W.C., Francke U. Widespread changes in dendritic and axonal morphology in Mecp2-mutant mouse models of Rett syndrome: evidence for disruption of neuronal networks. J. Comp. Neurol. 2009, 514:240-258.
11. Betancur C., Sakurai T., Buxbaum J.D. The emerging role of synaptic cell-adhesion pathways in the pathogenesis of autism spectrum disorders. Trends Neurosci. 2009, 32:402-412.
12. Borg I., Freude K., Kübart S., Hoffmann K., Menzel C., Laccone F., Firth H., Ferguson-Smith M.A., Tommerup N., Ropers H.H., Sargan D., Kalscheuer V.M. Disruption of Netrin G1 by a balanced chromosome translocation in a girl with Rett syndrome. Eur. J. Hum. Genet. 2005, 13:921-927.
13. Bozdagi O., Tavassoli T., Buxbaum J.D. Insulin-like growth factor-1 rescues synaptic and motor deficits in a mouse model of autism and developmental delay. Mol. Autism 2013, 4:9.
14. Buchovecky C.M., Turley S.D., Brown H.M., Kyle S.M., McDonald J.G., Liu B., Pieper A.A., Huang W., Katz D.M., Russell D.W., Shendure J., Justice M.J. A suppressor screen in Mecp2 mutant mice implicates cholesterol metabolism in Rett syndrome. Nat. Genet. 2013, 45:1013-1020.
15. Buschdorf J.P., Strätling W.H. A WW domain binding region in methyl-CpG-binding protein MeCP2: impact on Rett syndrome. J. Mol. Med. 2004, 82:135-143.
16. Capra V., Mirabelli-Badenier M., Stagnaro M., Rossi A., Tassano E., Gimelli S., Gimelli G. Identification of a rare 17p13.3 duplication including the BHLHA9 and YWHAE genes in a family with developmental delay and behavioural problems. BMC Med. Genet. 2012, 13:93.
17. Carro S., Bergo A., Mengoni M., Bachi A., Badaracco G., Kilstrup-Nielsen C., Landsberger N. A novel protein, Xenopus p20, influences the stability of MeCP2 through direct interaction. J. Biol. Chem. 2004, 279:25623-25631.
18. Chahrour M., Zoghbi H.Y. The story of Rett syndrome: from clinic to neurobiology. Neuron 2007, 56:422-437.
19. Chahrour M., Jung S.Y., Shaw C., Zhou X., Wong S.T., Qin J., Zoghbi H.Y. MeCP2, a key contributor to neurological disease, activates and represses transcription. Science 2008, 320:1224-1229.
20. Cheah P.S., Ramshaw H.S., Thomas P.Q., Toyo-Oka K., Xu X., Martin S., Coyle P., Guthridge M.A., Stomski F., van den Buuse M., Wynshaw-Boris A., Lopez A.F., Schwarz Q.P. Neurodevelopmental and neuropsychiatric behavior defects arise from 14-3-3 deficiency. Mol. Psychiatry 2012, 17:451-466.
21. Chen R.Z., Akbarian S., Tudor M., Jaenisch R. Deficiency of methyl-CpG binding protein-2 in CNS neurons results in a Rett-like phenotype in mice. Nat. Genet. 2001, 27(3):327-331.
22. Chen W.G., Chang Q., Lin Y., Meissner A., West A.E., Griffith E.C., Jaenisch R., Greenberg M.E. Derepression of BDNF transcription involves calcium-dependent phosphorylation of MeCP2. Science 2003, 302:855-889.
23. Cheval H., Guy J., Merusi C., De Sousa D., Selfridge J., Bird A. Postnatal inactivation reveals enhanced requirement for MeCP2 at distinct age windows. Hum. Mol. Genet. 2012, 21:3806-3814.
24. Cohen S., Greenberg M.E. A bird's-eye view of MeCP2 binding. Mol. Cell 2010, 37:451-452.
25. Cohen S., Gabel H.W., Hemberg M., Hutchinson A.N., Sadacca L.A., Ebert D.H., Harmin D.A., Greenberg R.S., Verdine V.K., Zhou Z., Wetsel W.C., West A.E., Greenberg M.E. Genome-wide activity-dependent MeCP2 phosphorylation regulates nervous system development and function. Neuron 2011, 72:72-85.
26. de Anda F.C., Rosario A.L., Durak O., Tran T., Gräff J., Meletis K., Rei D., Soda T., Madabhushi R., Ginty D.D., Kolodkin A.L., Tsai L.H. Autism spectrum disorder susceptibility gene TAOK2 affects basal dendrite formation in the neocortex. Nat. Neurosci. 2012, 15:1022-1031.
27. De Filippis B., Fabbri A., Simone D., Canese R., Ricceri L., Malchiodi-Albedi F., Laviola G., Fiorentini C. Modulation of RhoGTPases improves the behavioral phenotype and reverses astrocytic deficits in a mouse model of Rett syndrome. Neuropsychopharmacology 2012, 37:1152-1163.
28. Degano A.L., Pasterkamp R.J., Ronnett G.V. MeCP2 deficiency disrupts axonal guidance, fasciculation, and targeting by altering Semaphorin 3F function. Mol. Cell. Neurosci. 2009, 42:243-254.
29. Derecki N.C., Cronk J.C., Lu Z., Xu E., Abbott S.B., Guyenet P.G., Kipnis J. Wild-type microglia arrest pathology in a mouse model of Rett syndrome. Nature 2012, 484:105-109.
30. Dosztányi Z., Csizmok V., Tompa P., Simon I. IUPred: web server for the prediction of intrinsically unstructured regions of proteins based on estimated energy content. Bioinformatics 2005, 21:3433-3434.
31. Ebert D.H., Gabel H.W., Robinson N.D., Kastan N.R., Hu L.S., Cohen S., Navarro A.J., Lyst M.J., Ekiert R., Bird A.P., Greenberg M.E. Activity-dependent phosphorylation of MECP2 threonine 308 regulates interaction with NcoR. Nature 2013, 499(7458):341-345.
32. Forlani G., Giarda E., Ala U., Di Cunto F., Salani M., Tupler R., Kilstrup-Nielsen C., Landsberger N. The MeCP2/YY1 interaction regulates ANT1 expression at 4q35: novel hints for Rett syndrome pathogenesis. Hum. Mol. Genet. 2010, 19:3114-3123.
33. Frotscher M. Role for Reelin in stabilizing cortical architecture. Trends Neurosci. 2010, 33:407-414.
34. Fuks F., Hurd P.J., Wolf D., Nan X., Bird A.P., Kouzarides T. The methyl-CpG-binding protein MeCP2 links DNA methylation to histone methylation. J. Biol. Chem. 2003, 278:4035-4040.
35. Gamba P., Testa G., Sottero B., Gargiulo S., Poli G., Leonarduzzi G. The link between altered cholesterol metabolism and Alzheimer's disease. Ann. N. Y. Acad. Sci. 2012, 1259:54-64.
36. Georgel P.T., Horowitz-Schere R.A., Adkins N., Woodcock C.L., Wade P.A., Hansen J.C. Chromatin compaction by human MeCP2. Assembly of novel secondary chromatin structures in the absence of DNA methylation. J. Biol. Chem. 2003, 278:32181-32188.
37. Ghosh R.P., Nikitina T., Horowitz-Scherer R.A., Gierasch L.M., Uversky V.N., Hite K., Hansen J.C., Woodcock C.L. Unique physical properties and interactions of the domains of methylated DNA binding protein 2. Biochemistry 2010, 49:4395-4410.
38. Goffin D., Allen M., Zhang L., Amorim M., Wang I.T., Reyes A.R., Mercado-Berton A., Ong C., Cohen S., Hu L., Blendy J.A., Carlson G.C., Siegel S.J., Greenberg M.E., Zhou Z. Rett syndrome mutation MeCP2 T158A disrupts DNA binding, protein stability and ERP responses. Nat. Neurosci. 2011, 15(2):274-283.
39. Gonzales M.L., Adams S., Dunaway K.W., LaSalle J.M. Phosphorylation of distinct sites in MeCP2 modifies cofactor associations and the dynamics of transcriptional regulation. Mol. Cell. Biol. 2012, 32:2894-2903.
40. Grosser E., Hirt U., Janc O.A., Menzfeld C., Fischer M., Kempkes B., Vogelgesang S., Manzke T.U., Opitz L., Salinas-Riester G., Müller M. Oxidative burden and mitochondrial dysfunction in a mouse model of Rett syndrome. Neurobiol. Dis. 2012, 48:102-114.
41. Guy J., Hendrich B., Holmes M., Martin J.E., Bird A. A mouse Mecp2-null mutation causes neurological symptoms that mimic Rett syndrome. Nat. Genet. 2001, 27(3):322-326.
42. Guy J., Gan J., Selfridge J., Cobb S., Bird A. Reversal of neurological defects in a mouse model of Rett syndrome. Science 2007, 315:1143-1147.
43. Guy J., Cheval H., Selfridge J., Bird A. The role of MeCP2 in the brain. Annu. Rev. Cell Dev. Biol. 2011, 227:631-652.
44. Hansen J.C., Ghosh R.P., Woodcock C.L. Binding of the Rett syndrome protein, MeCP2, to methylated and unmethylated DNA and chromatin. Life 2010, 62:732-738.
45. Haraguchi S., Sasahara K., Shikimi H., Honda S., Harada N., Tsutsui K. Estradiol promotes Purkinje dendritic growth, spinogenesis, and synaptogenesis during neonatal life by inducing the expression of BDNF. Cerebellum 2012, 11:416-417.
46. Harikrishnan K.N., Chow M.Z., Baker E.K., Pal S., Bassal S., Brasacchio D., Wang L., Craig J.M., Jones P.L., Sif S., El-Osta A. Brahma links the SWI/SNF chromatin-remodeling complex with MeCP2-dependent transcriptional silencing. Nat. Genet. 2005, 37:254-264.
47. Hite K.C., Kalashnikova A.A., Hansen J.C. Coil-to-helix transitions in intrinsically disordered methyl CpG binding protein 2 and its isolated domains. Protein Sci. 2012, 21:531-538.
48. Ho K.L., McNae I.W., Schmiedeberg L., Klose R.J., Bird A.P., Walkinshaw M.D. MeCP2 binding to DNA depends upon hydration at methyl-CpG. Mol. Cell 2008, 29:525-531.
49. Hutchinson A.N., Deng J.V., Cohen S., West A.E. Phosphorylation of MeCP2 at Ser421 contributes to chronic antidepressant action. J. Neurosci. 2012, 32(41):14355-14363.
50. Itoh M., Ide S., Takashima S., Kudo S., Nomura Y., Segawa M., Kubota T., Mori H., Tanaka S., Horie H., Tanabe Y., Goto Y. Methyl CpG-binding protein 2 (a mutation of which causes Rett syndrome) directly regulates insulin-like growth factor binding protein 3 in mouse and human brains. J. Neuropathol. Exp. Neurol. 2007, 66:117-123.
51. Itoh M., Tahimic C.G., Ide S., Otsuki A., Sasaoka T., Noguchi S., Oshimura M., Goto Y., Kurimasa A. Methyl CpG-binding protein isoform MeCP2_e2 is dispensable for Rett syndrome phenotypes but essential for embryo viability and placenta development. J. Biol. Chem. 2012, 287:13859-13867.
52. Jeffery L., Nakienly S. Components of the DNA methylation system of chromatin control are RNA-binding proteins. J. Biol. Chem. 2004, 279:49479-49487.
53. Jentarra G.M., Olfers S.L., Rice S.G., Srivastava N., Homanics G.E., Blue M., Naidu S., Narayanan V. Abnormalities of cell packing density and dendritic complexity in the MeCP2 A140V mouse model of Rett syndrome/X-linked mental retardation. BMC Neurosci. 2010, 10.1186/1471-2202-11-19.
54. Jones P.L., Veenstra G.J., Wade P.A., Vermaak D., Kass S.U., Landsberger N., Strouboulis J., Wolffe A.P. Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat. Genet. 1998, 19:187-191.
55. Jugloff D.G., Vandamme K., Logan R., Visanji N.P., Brotchie J.M., Eubanks J.H. Targeted delivery of an Mecp2 transgene to forebrain neurons improves the behavior of female Mecp2-deficient mice. Hum. Mol. Genet. 2008, 17:1386-1396.
56. Kimura H., Shiota K. Methyl-CpG-binding protein, MeCP2, is a target molecule for maintenance DNA methyltransferase, Dnmt1. J. Biol. Chem. 2003, 278:4806-4812.
57. Kokura K., Kaul S.C., Wadhwa R., Nomura T., Khan M.M., Shinagawa T., Yasukawa T., Colmenares C., Ishii S. The Ski protein family is required for MeCP2-mediated transcriptional repression. J. Biol. Chem. 2001, 276:34115-34121.
58. Kriaucionis S., Bird A. The major form of MeCP2 has a novel N-terminus generated by alternative splicing. Nucleic Acids Res. 2004, 32:1818-1823.
59. Kudo S., Nomura Y., Segawa M., Fujita N., Nakao M., Schanen C., Tamura M. Heterogeneity in residual function of MeCP2 carrying missense mutations in the methyl CpG binding domain. J. Med. Genet. 2003, 40:487-493.
60. Lawson-Yuen A., Liu D., Han L., Jiang Z.I., Tsai G.E., Basu A.C., Picker J., Feng J., Coyle J.T. Ube3a mRNA and protein expression are not decreased in Mecp2R168X mutant mice. Brain Res. 2007, 1180:1-6.
61. Lee R.W., Tierney E. Hypothesis: the role of sterols in autism spectrum disorder. Autism Res. Treat. 2011, 2011:653570.
62. Lekman A.Y., Hagberg B.A., Svennerholm L.T. Membrane cerebral lipids in Rett syndrome. Pediatr. Neurol. 1991, 7:186-190.
63. Lesma E., Ancona S., Orpianesi E., Grande V., Di Giulio A.M., Gorio A. Chromatin remodeling by rosuvastatin normalizes TSC2-/meth cell phenotype through the expression of tuberin. J. Pharmacol. Exp. Ther. 2013, 345:180-188.
64. Lessey E.C., Guilluy C., Burridge K. From mechanical force to RhoA activation. Biochemistry 2012, 51:7420-7432.
65. Lewis J.D., Meehan R.R., Henzel W.J., Maurer-Fogy I., Jeppesen P., Klein F., Bird A. Purification, sequence, and cellular localization of a novel chromosomal protein that binds to methylated DNA. Cell 1992, 69:905-914.
66. Li H., Zhong X., Chau K.F., Williams E.C., Chang Q. Loss of activity-induced phosphorylation of MeCP2 enhances synaptogenesis, LTP and spatial memory. Nat. Neurosci. 2011, 14(8):1001-1008.
67. Li W., Pozzo-Miller L. BDNF deregulation in Rett syndrome. Nauropharmacology 2013.
68. Lioy D.T., Garg S.K., Monaghan C.E., Raber J., Foust K.D., Kaspar B.K., Hirrlinger P.G., Kirchhoff F., Bissonnette J.M., Ballas N., Mandel G. A role for glia in the progression of Rett's syndrome. Nature 2011, 475:497-500.
69. Lyst M.J., Ekiert R., Ebert D.H., Merusi C., Nowak J., Selfridge J., Guy J., Kastan N.R., Robinson N.D., de Lima Alves F., Rappsilber J., Greenberg M.E., Bird A. Rett syndrome mutations abolish the interaction of MeCP2 with the NCoR/SMRT co-repressor. Nat. Neurosci. 2013, 16:898-902.
70. Long S.W., Ooi J.Y., Yau P.M., Jones P.L. A brain-derived MeCP2 complex supports a role for MeCP2 in RNA processing. Biosci. Rep. 2011, 31:333-343.
71. Lunyak V.V., Burgess R., Prefontaine G.G., Nelson C., Sze S.H., Chenoweth J., Schwartz P., Pevzner P.A., Glass C., Mandel G., Rosenfeld M.G. Corepressor-dependent silencing of chromosomal regions encoding neuronal genes. Science 2002, 298:1747-1752.
72. Maezawa I., Swanberg S., Harvey D., LaSalle J.M., Jin L.W. Rett syndrome astrocytes are abnormal and spread MeCP2 deficiency through gap junctions. J. Neurosci. 2009, 29:5051-5061.
73. Maezawa I., Jin L.W. Rett syndrome microglia damage dendrites and synapses by the elevated release of glutamate. J. Neurosci. 2010, 30:5346-5356.
74. Matsumura S., Persson L.M., Wong L., Wilson A.C. The latency-associated nuclear antigen interacts with MeCP2 and nucleosomes through separate domains. J. Virol. 2010, 84:2318-2330.
75. McGraw C.M., Samaco R.C., Zoghbi H.Y. Adult neural function requires MeCP2. Science 2011, 333:186.
76. Mellén M., Ayata P., Dewell S., Kriaucionis S., Heintz N. MeCP2 binds to 5hmC enriched within active genes and accessible chromatin in the nervous system. Cell 2012, 151:1417-1430.
77. Meng Q., Xia Y. C-Jun, at the crossroad of the signaling network. Protein Cell 2011, 2:889-898.
78. Miyake K., Nagai K. Phosphorylating of methyl-CpG binding protein 2 (MeCP2) regulates the intracellular localization during neuronal cell differentiation. Neurochem. Int. 2007, 50:264-270.
79. Mnatzakanian G.N., Lohi H., Munteanu I., Alfred S.E., Yamada T., MacLeod P.J., Jones J.R., Scherer S.W., Schanen N.C., Friez M.J., Vincent J.B., Minassian B.A. A previously unidentified MECP2 open reading frame defines a new protein isoform relevant to Rett syndrome. Nat. Genet. 2004, 36:339-341.
80. Moretti P., Levenson J.M., Battaglia F., Atkinson R., Teague R., Antalffy B., Armstrong D., Arancio O., Sweatt J.D., Zoghbi H.Y. Learning and memory and synaptic plasticity are impaired in a mouse model of Rett syndrome. J. Neurosci. 2006, 26(1):319-327.
81. Muotri A.R., Marchetto M.C., Coufal N.G., Oefner R., Yeo G., Nakashima K., Gage F.H. L1 retrotransposition in neurons is modulated by MeCP2. Nature 2010, 468:443-446.
82. Nan X., Campoy F.J., Bird A. MeCP2 is a transcriptional repressor with abundant binding sites in genomic chromatin. Cell 1997, 88:471-481.
83. Nan X., Hou J., Maclean A., Nasir J., Lafuente M.J., Shu X., Kriaucionis S., Bird A. Interaction between chromatin proteins MECP2 and ATRX is disrupted by mutations that cause inherited mental retardation. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:2709-2714.
84. Nectoux J., Girard B., Bahi-Buisson N., Prieur F., Afenjar A., Rosas-Vargas H., Chelly J., Bienvenu T. Netrin G1 mutations are an uncommon cause of atypical Rett syndrome with or without epilepsy. Pediatr. Neurol. 2007, 37:270-274.
85. Nectoux J., Fichou Y., Rosas-Vargas H., Cagnard N., Bahi-Buisson N., Nusbaum P., Letourneur F., Chelly J., Bienvenu T. Cell cloning-based transcriptome analysis in Rett patients: relevance to the pathogenesis of Rett syndrome of new human MeCP2 target genes. J. Cell. Mol. Med. 2010, 14:1962-1974.
86. Neul J.L., Kaufmann W.E., Glaze D.G., Christodoulou J., Clarke A.J., Bahi-Buisson N., Leonard H., Bailey M.E., Schanen N.C., Zappella M., Renieri A., Huppke P., Percy A.K. Rett syndrome: revised diagnostic criteria and nomenclature. Ann. Neurol. 2010, 68:944-950.
87. Ng H.H., Zhang Y., Hendrich B., Johnson C.A., Turner B.M., Erdjument-Bromage H., Tempst P., Reinberg D., Bird A. MBD2 is a transcriptional repressor belonging to the MeCP1 histone deacetylase complex. Nat. Genet. 1999, 23:58-61.
88. Nguyen M.V., Du F., Felice C.A., Shan X., Nigam A., Mandel G., Robinson J.K., Ballas N. MeCP2 is critical for maintaining mature neuronal networks and global brain anatomy during late stages of postnatal brain development and in the mature adult brain. J. Neurosci. 2012, 32:10021-10034.
89. Pavlowsky A., Zanchi A., Pallotto M., Giustetto M., Chelly J., Sala C., Billuart P. Neuronal JNK pathway activation by IL-1 is mediated through IL1RAPL1, a protein required for development of cognitive functions. Commun. Integr. Biol. 2010, 3:245-247.
90. Pavlowsky A., Gianfelice A., Pallotto M., Zanchi A., Vara H., Khelfaoui M., Valnegri P., Rezai X., Bassani S., Brambilla D., Kumpost J., Blahos J., Roux M.J., Humeau Y., Chelly J., Passafaro M., Giustetto M., Billuart P., Sala C. A postsynaptic signaling pathway that may account for the cognitive defect due to IL1RAPL1 mutation. Curr. Biol. 2010, 20:103-115.
91. Percy A.K., Lane J.B. Rett syndrome: model of neurodevelopmental disorders. J. Child Neurol. 2005, 20:718-721.
92. Pini G., Scusa M.F., Congiu L., Benincasa A., Morescalchi P., Bottiglioni I., Di Marco P., Borelli P., Bonuccelli U., Della-Chiesa A., Prina-Mello A., Tropea D. IGF1 as a potential treatment for Rett Syndrome: safety assessment in six Rett patients. Autism Res. Treat. 2012, 2012:679801.
93. Pitcher M.R., Ward C.S., Arvide E.M., Chapleau C.A., Pozzo-Miller L., Hoeflich A., Sivaramakrishnan M., Saenger S., Metzger F., Neul J.L. Insulinotropic treatments exacerbate metabolic syndrome in mice lacking MeCP2 function. Hum. Mol. Genet. 2013, 22:2626-2633.
94. Ricceri L., De Filippis B., Laviola G. Mouse models of Rett syndrome: from behavioural phenotyping to preclinical evaluation of new therapeutic approaches. Behav. Pharmacol. 2008, 19:501-517.
95. Ricciardi S., Boggio E.M., Grosso S., Lonetti G., Forlani G., Stefanelli G., Calcagno E., Morello N., Landsberger N., Biffo S., Pizzorusso T., Giustetto M., Broccoli V. Reduced AKT/mTOR signaling and protein synthesis dysregulation in a Rett syndrome animal model. Hum. Mol. Genet. 2011, 20:1182-1196.
96. Skene P.J., Illingworth R.S., Webb S., Kerr A.R., James K.D., Turner D.J., Andrews R., Bird A.P. Neuronal MeCP2 is expressed at near histone-octamer levels and globally alters the chromatin state. Mol. Cell 2010, 37:457-468.
97. Smrt R.D., Eaves-Egenes J., Barkho B.Z., Santistevan N.J., Zhao C., Aimone J.B., Gage F.H., Zhao X. Mecp2 deficiency leads to delayed maturation and altered gene expression in hippocampal neurons. Neurobiol. Dis. 2007, 27:77-89.
98. Song C., Kokontis J.M., Hiipakka R.A., Liao S. Ubiquitous receptor: a receptor that modulates gene activation by retinoic acid and thyroid hormone receptors. Proc. Natl. Acad. Sci. U.S.A. 1994, 91:10809-10813.
99. Suzuki M., Yamada T., Kihara-Negishi F., Sakurai T., Oikawa T. Direct association between PU.1 and MeCP2 that recruits mSin3A-HDAC complex for PU.1-mediated transcriptional repression. Oncogene 2003, 22:8688-8698.
100. Suzuki S., Kiyosue K., Hazama S., Ogura A., Kashihara M., Hara T., Koshimizu H., Kojima M. Brain-derived neurotrophic factor regulates cholesterol metabolism for synapse development. J. Neurosci. 2007, 27:6417-6427.
101. Tao J., Hu K., Chang Q., Wu H., Sherman N.E., Martinowich K., Klose R.J., Schanen C., Jaenisch R., Wang W., Sun Y.E. Phosphorylation of MeCP2 at Serine 80 regulates its chromatin association and neurological function. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:4882-4887.
102. Thambirajah A.A., Eubanks J.H., Ausió J. MeCP2 post-translational regulation through PEST domains: two novel hypotheses: potential relevance and implications for Rett syndrome. Bioessays 2009, 31:561-569.
103. Tropea D., Giacometti E., Wilson N.R., Beard C., McCurry C., Fu D.D., Flannery R., Jaenisch R., Sur M. Partial reversal of Rett syndrome-like symptoms in MeCP2 mutant mice. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:2029-2034.
104. Tsutsui K. Neurosteroid biosynthesis and action during cerebellar development. Cerebellum 2012, 11:414-415.
105. Urdinguio R.G., Lopez-Serra L., Lopez-Nieva P., Alaminos M., Diaz-Uriarte R., Fernandez A.F., Esteller M. Mecp2-null mice provide new neuronal targets for Rett syndrome. PLoS One 2008, 3(11):e3669.
106. Valenza M., Cattaneo E. Emerging roles for cholesterol in Huntington's disease. Trends Neurosci. 2011, 34:474-486.
107. Viola A., Saywell V., Villard L., Cozzone P.J., Lutz N.W. Metabolic fingerprints of altered brain growth, osmoregulation and neurotransmission in a Rett syndrome model. PLoS One 2007, 2:e157.
108. Wang I.T., Allen M., Goffin D., Zhu X., Fairless A.H., Brodkin E.S., Siegel S.J., Marsh E.D., Blendy J.A., Zhou Z. Loss of CDKL5 disrupts kinome profile and event-related potentials leading to autistic-like phenotypes in mice. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:21516-21521.
109. Willy P.J., Umesono K., Ong E.S., Evans R.M., Heyman R.A., Mangelsdorf D.J. LXR, a nuclear receptor that defines a distinct retinoid response pathway. Genes Dev. 1995, 9:1033-1045.
110. Woods A.G., Sokolowska I., Taurines R., Gerlach M., Dudley E., Thome J., Darie C.C. Potential biomarkers in psychiatry: focus on the cholesterol system. J. Cell. Mol. Med. 2012, 16:1184-1195.
111. Wu H., Lu D., Jiang H., Xiong Y., Qu C., Li B., Mahmood A., Zhou D., Chopp M. Simvastatin-mediated upregulation of VEGF and BDNF, activation of the PI3K/Akt pathway, and increase of neurogenesis are associated with therapeutic improvement after traumatic brain injury. J. Neurotrauma 2008, 25:130-139.
112. Young J.I., Hong E.P., Castle J.C., Crespo-Barreto J., Bowman A.B., Rose M.F., Kang D., Richman R., Johnson J.M., Berget S., Zoghbi H.Y. Regulation of RNA splicing by the methylation-dependent transcriptional repressor methyl-CpG binding protein 2. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:17551-17558.
113. Yusufzai T.M., Wolffe A.P. Functional consequences of Rett syndrome mutations on human MeCP2. Nucleic Acids Res. 2000, 28:4172-4179.
114. Zhou Z., Hong E.J., Cohen S., Zhao W.N., Ho H.Y., Schmidt L., Chen W.G., Lin Y., Savner E., Griffith E.C., Hu L., Steen J.A., Weitz C.J., Greenberg M.E. Brain-specific phosphorylation of MeCP2 regulates activity-dependent Bdnf transcription, dendritic growth, and spine maturation. Neuron 2006, 52:255-269.
115. Ziats M.N., Rennert O.M. Expression profiling of autism candidate genes during human brain development implicates central immune signaling pathways. PLoS One 2011, 6:e24691.